2.34
0.09 (4.24%)
| Penutupan Terdahulu | 2.24 |
| Buka | 2.26 |
| Jumlah Dagangan | 164,180 |
| Purata Dagangan (3B) | 395,255 |
| Modal Pasaran | 220,855,136 |
| Harga / Pendapatan (P/E TTM) | 6.14 |
| Harga / Jualan (P/S) | 2.90 |
| Harga / Buku (P/B) | 2.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | -51.27% |
| Margin Operasi (TTM) | -367.56% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -10.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.85% |
| Nisbah Semasa (MRQ) | 5.09 |
| Aliran Tunai Operasi (OCF TTM) | 49.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 49.31 M |
| Pulangan Atas Aset (ROA TTM) | -8.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -24.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Compugen Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 2.5 |
| Purata | -0.33 |
|
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.12% |
| % Dimiliki oleh Institusi | 17.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Taylor Frigon Capital Management Llc | 30 Jun 2026 | 842,181 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |